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Abstract
Background: Long-acting opioid formulations are advocated for maintaining pain control in
chronic cancer pain. OROS® hydromorphone is a sustained-release formulation of hydromor-
phone that requires dosing once daily to maintain therapeutic concentrations. The objective of this
study was to demonstrate the clinical equivalence of immediate-release and sustained-release
formulations of hydromorphone and morphine for chronic cancer pain.
Methods: 200 patients with cancer pain (requiring ≤ 540 mg/d of oral morphine) participated in this
double-blind, parallel-group trial. Patients were randomized to receive hydromorphone or morphine
(immediate-release for 2–9 days, sustained-release for 10–15 days). Efficacy was assessed with the Brief
Pain Inventory (BPI), investigator and patient global evaluations, Eastern Cooperative Oncology Group
performance status, and the Mini-Mental State Examination. The primary endpoint was the 'worst pain in
the past 24 hours' item of the BPI, in both the immediate-release and sustained-release study phases, with
treatments deemed equivalent if the 95% confidence intervals (CI) of the between-group differences at
endpoint were between 1.5 and 1.5. No equivalence limits were defined for secondary endpoints.
Results: Least-squares mean differences (95% CI) between groups were 0.2 (0.4, 0.9) in the
immediate-release phase and 0.8 (1.6, 0.01) in the sustained-release phase (intent-to-treat
population), indicating that the immediate-release formulationsmet the pre-specified equivalence criteria,
but that the lower limit of the 95% CI (1.6) was outside the boundary (1.5) for the sustained-release
formulations. BPI 'pain now PM' was significantly lower with OROS® hydromorphone compared with
controlled-release morphine (least-squares mean difference [95%CI],0.77 [-1.49,0.05]; p = 0.0372).
Scores for other secondary efficacy variables were similar between the two sustained-release treatments.
At endpoint, > 70% of investigators and patients rated both treatments as good to excellent. The safety
profiles of hydromorphone and morphine were similar and typical of opioid analgesics.
Conclusion: Equivalence was demonstrated for immediate-release formulations of hydromorphone
and morphine, but not for the sustained-release formulations of OROS® hydromorphone and
controlled-release morphine. The direction of the mean difference between the treatments (0.8) and
the out-of-range lower limit of the 95% CI (1.6) were in favor of OROS® hydromorphone.
Trial registration: ClinicalTrials.gov: NCT0041054
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Background
Opioid analgesics are highly effective for the treatment
of pain, enabling 85% to 95% of patients to gain
functional control of their lives [1, 2]. Opioid therapy is
typically initiated after the failure of maximum doses of
non-opioid analgesics [3] and is titrated to attain the
best balance between pain relief and side effects for each
patient. The European Association for Palliative Care [4]
and the American Pain Society [5] advocate the use of
long-acting oral agents for maintaining analgesia once
individual dose requirements have been established. For
these reasons, long-acting opioids have become the
mainstay of chronic cancer pain therapy.
OROS® hydromorphone is a unique long-acting opioid
formulation that utilizes Push-Pull™ active osmotic
technology developed by ALZA Corporation (Mountain
View, CA, USA). The Push-Pull™ system maintains
consistent hydromorphone plasma concentrations
throughout the 24-hour dosing interval, providing
long-lasting analgesia [6–8]. Release of the drug from
the system is actively controlled by the dosage form
itself, and is not significantly influenced by environ-
mental factors such as the surrounding pH or gastric
motility [9, 10]. There is a minimal effect of food on the
rate and extent of absorption of hydromorphone from
OROS® hydromorphone; in one study the mean
geometric ratios of fed and fasted subjects for peak
plasma concentration (Cmax) and area under the con-
centration-time curve (AUC) were within 20%; the
median time to peak plasma concentration (Tmax) was
lower under fed conditions (12 versus 16 hours), but
mean plasma concentration profiles generally over-
lapped, especially up to 6 hours after dosing [11]. The
pharmacokinetics of OROS® hydromorphone are also
minimally affected by alcohol; one study found that
plasma hydromorphone concentrations were slightly
higher after alcohol (240 mL solutions of 4%, 20%,
and 40% alcohol and orange juice) compared with no
alcohol, but there was no clear alcohol dose-response
relationship and no dose dumping of hydromorphone
occurred [12].
The primary objective of the current study was to
demonstrate the clinical equivalence of hydromorphone
and morphine (immediate-release [IR] and sustained-
release [SR] formulations) using the 'worst pain in the
past 24 hours' item of the Brief Pain Inventory (BPI).
Morphine was selected as the active comparator since it
is the gold standard for pain control. Controlled-release
(CR) morphine is available in twice-daily and once-daily
formulations and is widely used to alleviate cancer pain;
in this study the twice-daily formulation (dosing every
12 hours) was used.
Methods
Patients
This study was a multicenter, phase III, randomized,
double-blind (double-dummy), active-controlled, paral-
lel-group, equivalence trial. It was conducted at 37
centers in Belgium, Canada, France, Germany, The
Netherlands, Spain, Sweden, and the United Kingdom.
The study enrolled inpatients, outpatients, and day-
patients ≥ 18 years of age who had moderate to severe
chronic cancer pain requiring 60 to 540 mg of oral
morphine (or equivalent) every 24 hours. The criteria
used for patient selection are listed in Table 1.
Concomitant chemotherapy or radiotherapy was per-
mitted. All patients who entered the trial were informed
of the nature of the study, and provided written
informed consent for participation. The study was
conducted in accordance with the principles of the
Declaration of Helsinki.
Drugs and dosages
Patients were randomized 1:1, with a central computer-
generated randomization list, to receive hydromorphone
or morphine for up to 24 days (Figure 1). This study
consisted of 2 phases: an initial IR phase and a subsequent
SR phase. In the IR phase, patients received IR formulations
of either hydromorphone [Dilaudid®, Abbott Laboratories]
or morphine (morphine sulfate IR [Sevredol®, Napp
Laboratories]) every 4 hours (6 times daily) for 2 to 9
days. Patients underwent conversion from previous therapy
to 1 of 6 possible initial dose levels, based on individual
patient characteristics and generally accepted morphine
equivalent conversion factors. Doses were selected accord-
ing to the available tablet strengths and a working
conversion ratio of 1:5 (1 hydromorphone:5 morphine
equivalents), in the ranges hydromorphone IR 12–108 mg/
day and morphine IR 60–540 mg/day. The dose was
titrated to the next higher dose level if the patient had more
than 3 breakthrough pain episodes requiring breakthrough
pain medication within the previous 24 hours. Daily doses
were titrated up to the next higher dose level, with no dose
levels skipped, at most once a day. Dose titration was
continued until dose-stable pain control was achieved.
Patients who experienced 2 consecutive days with no more
than 3 breakthrough pain episodes requiring rescue
medication per day were considered to have achieved
dose-stable pain control and could begin the SR phase of
the study. Patients who did not achieve dose stable pain
control by day 9 were withdrawn from the study, and end-
of-study evaluations were carried out.
The duration of the SR phase was 10 to 15 days. In this
phase, patients continued to receive the same study drug
but in an SR formulation: OROS® hydromorphone once-
daily or CR morphine (morphine sulfate SR [MST
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Continus®, Napp Laboratories]) twice-daily. They were
started on the same dose level number on which they had
achieved dose-stable pain control in the preceding IR
phase, which was then adjusted as required, at most every 2
days, in single steps so that no dose level was skipped.
Doses were selected according to the available tablet
strengths and a working conversion ratio of approximately
1:5 (hydromorphone:morphine), in the ranges OROS®
hydromorphone 16–96 mg/day and CR morphine 60–520
mg/day. The SR phase was completed after a minimum of
10 days (maximum of 15 days) on OROS® hydromor-
phone or CR morphine if pain was controlled and the dose
was stable for at least the previous 2 days.
In the IR phase, the dosing regimen was the same for both
drugs: patients received a dose of study medication 6 times
a day, every 4 hours, at 0600, 1000, 1400, 1800, 2200, and
0200. In this phase, all treatments were over-encapsulated
resulting in identical capsules. In the SR phase, dosing was
done twice each day at 1000 and 2200. To maintain the
blind in this phase, matching placebo tablets and capsules
were used: patients in the OROS® hydromorphone group
took OROS® hydromorphone and placebo CR morphine
in the morning and placebo CR morphine in the evening;
patients in the CR morphine group took CR morphine and
placebo OROS® hydromorphone in the morning and CR
morphine in the evening.
In both study phases, patients could also receive break-
through pain medication as needed, either hydromor-
phone or morphine, supplied as the IR formulation. A
single dose of breakthrough pain medication contained
approximately one-sixth of the patient's daily dose.
Assessments
Baseline efficacy assessments were done before dosing
on day 1 of the IR phase and included: the BPI (12-item
instrument to assess pain intensity [from 0 = no pain to
10 = pain as bad as you can imagine], pain relief [0% to
100%], and pain interference with various aspects of the
patient's life [from 0 = no interference to 10 = complete
interference]) [13], the Mini-Mental State Examination
(MMSE; 0–30, higher scores indicate better cognitive
performance) [14], and the Eastern Cooperative Oncol-
ogy Group (ECOG) performance status score (0–4,
higher scores indicate poorer performance) [15].
Primary equivalence of efficacy was assessed using the
BPI assessment of 'worst pain in the past 24 hours' on an
Table 1: Criteria for patient selection
Inclusion criteria Exclusion criteria
• Age ≥ 18 years • Pain not considered potentially responsive to opioids
• Presence of chronic cancer pain: • Pain present only upon movement
◦ currently receiving strong oral or transdermal opioid analgesics
(60–540 mg oral morphine or equivalent every 24 hours)
• Need for other opioid analgesics (except study medication and
breakthrough pain medication) after randomization
◦ appropriate candidate for strong oral or transdermal opioid
analgesics (anticipated requirement, 60–540 mg oral morphine or
equivalent every 24 hours)
• Current or recent (within 6 months) history of drug and/or alcohol
abuse
• Pain suitable for treatment with a once-daily formulation • Women of childbearing potential who are pregnant or lactating, seeking
pregnancy, or failing to take adequate contraceptive precautions
• Intolerance of, or hypersensitivity to, hydromorphone or other opioids
• Presence of GI disease of sufficient severity to likely interfere with oral
analgesia (e.g., dysphagia, vomiting, no bowel movement or bowel
obstruction due to impaction within 5 days of study entry, severe gut
narrowing that may affect analgesic absorption or transit)
• Use of monoamine oxidase inhibitors within 2 weeks prior to study
entry
• Investigational drug use within 4 weeks of study entry
• Presence of conditions for which risks of opioid use outweigh potential
benefits (e.g., raised intracranial pressure, hypotension, hypothyroidism,
asthma, reduced respiratory reserve, prostatic hypertrophy, hepatic
impairment, renal impairment, elderly and debilitated, convulsive
disorders, Addison's disease)
Abbreviation: GI, gastrointestinal
Figure 1
Study design. BID, twice daily; CR, controlled-release; IR,
immediate-release; QD, once-daily; q4h, every 4 hours.
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11-point scale ranging from 0 (no pain) to 10 (worst
pain imaginable). This was selected as the primary
efficacy measure because evidence suggests that severely
intense pain is what interferes most significantly with
activities of daily life [13]. Secondary endpoints included
other assessments of pain from the BPI (completed by
the investigator in consultation with the patient);
investigator and patient global assessments of treatment
effectiveness (1 = poor, 2 = fair, 3 = good, 4 = very good,
5 = excellent); MMSE; ECOG; time to dose stabilization;
and usage and dose of breakthrough pain medication.
Patients ratedBPI 'worst pain in the past 24hours' once daily
(just before taking the mid-morning dose of study medica-
tion) and 'pain now' twice daily (AM and PM; just before
taking themid-morning and evening doses) throughout the
study and recorded responses in daily diaries. The other BPI
assessments, plus investigator andpatient global evaluations
of treatment effectiveness, MMSE, and ECOG, were evalu-
ated at the end of both phases.
Adverse events (AEs) and concomitant medications were
recorded throughout the study. Physical examinations were
carried out at baseline and at the end of each study phase.
Blood and urine samples were collected for laboratory
analysis (hematology, serum biochemistry, and urinalysis)
at baseline and at the end of the SR phase.
Patients were contacted daily during the IR phase and
every 3 to 4 days during the SR phase (preferably by
home or clinic visit, or by telephone if appropriate).
Contact was also made 3 days after the last dose of study
drug to determine the patient's AE status.
Statistical analysis
Assuming variability (standard deviation, SD) in the
primary efficacy variable of 2.0 [16] and a 30% dropout/
non-evaluable rate, a sample size of approximately 70
patients per treatment group was required (140 total).
This would provide 90% power to detect equivalence
with an equivalence limit of 1.5. A planned blinded re-
estimation of the optimal sample size was done by an
appointed independent person after 55 patients had
completed the study, the variability for the primary
efficacy measure was estimated using their data, and the
sample size was increased to 170 patients. Subsequently,
an unplanned, blinded re-estimation of the variability of
the primary variable for both phases was done after 120
patients had completed the study, and as a result, the
sample size was increased to 200 patients.
All statistical analyses were pre-specified. All efficacy
variables were analyzed using the intent-to-treat (ITT)
population, which included all patients who took at
least 1 dose of study medication and had at least 1
assessment from each study phase. A per-protocol (PP)
analysis, excluding data from patients with major
protocol deviations, was also done. All patients taking
at least 1 dose of study medication were included in the
analysis of safety. All efficacy analyses included a pre-
specified adjustment for baseline value and country to
control for potentially confounding variables.
The primary efficacy analysis used the mean of the last 2
post-baseline recorded values (or the last value if only 1
was available) for BPI 'worst pain in the past 24 hours'.
The primary measure was calculated separately for the IR
and SR phases (there were therefore two primary
outcomes). An analysis of covariance (ANCOVA) was
used to calculate the 95% two-sided confidence interval
(CI) for the difference between the adjusted means for
the 2 treatments at endpoint of each phase. An
equivalence test was used to compare the mean scores
of the primary efficacy me+asure at the end of each phase
[17–19]. The 2 treatments, within a phase, were
considered equivalent if the 95% two-sided CI for the
treatment difference was within a 1.5 and 1.5 point
difference on the BPI scale. This particular CI range was
selected prospectively because it was considered clini-
cally relevant through consultation with physicians who
specialize in analgesia.
For secondary endpoints (including BPI 'pain at its least
in past 24 hours', 'pain on average pain', 'pain now' (AM
and PM), 'pain relief in past 24 hours', 'pain interference
in past 24 hours', MMSE, and ECOG) an ANCOVA
model was used to calculate 95% two-sided CIs for the
difference between the adjusted treatment means at the
end of the IR and SR phases. The adjusted means were
estimated by the same approach used for the primary
endpoint, with the baseline score designated as a
covariate; however, no equivalence limits were specified
for the secondary endpoints. Time to dose stabilization
during both study phases was analyzed by the log-rank
test. Summary statistics with 95% CIs were produced for
investigator and patient global evaluations of treatment
effectiveness and to assess the number of medication
doses taken for breakthrough pain in the last 2 days of
each phase. P values (not adjusted for multiple
comparisons) are reported for secondary endpoints.
Statistical significance was declared at the a = 0.05 level.
Results
Study population
202 patients were enrolled into the study (Belgium, n = 29;
Canada, n = 10; France, n = 7; Germany, n = 15;
Netherlands, n = 29; Spain, n = 41; Sweden, n = 11; UK,
n = 60). 200 patients were randomized and took study
BMC Palliative Care 2008, 7:17 http://www.biomedcentral.com/1472-684X/7/17
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medication. 163 patients (81.5%) completed the IR phase
and 133 (66.5%) completed the SR phase. Figure 2 is a flow
diagramof patient entry and completion and the reasons for
premature discontinuation. Withdrawal from the study
owing to lack of efficacy was more common in patients
randomized to hydromorphone (n = 11) compared with
morphine (n = 4). The mean age of participants overall was
59.8 years. 98.5% of patients were Caucasian and 51%were
female. The most common types of cancer were breast
(28%), lung (20%), and gastrointestinal (16%). For 133
(67%) patients, the predominant pain location was bone or
soft tissue; 34 (17%) others had mixed pain, and 33 (17%)
had visceral pain. No patient had neuropathic pain. The
most common pain medications used at study entry were
morphine (n = 124 [62%]) and tramadol (n = 38 [19%]).
The baseline demographics and clinical characteristics were
similar for both treatment groups (Table 2).
Efficacy
BPI 'worst pain in the past 24 hours' (primary endpoint)
In each study phase, mean values for BPI 'worst pain in the
past 24 hours' decreased with both hydromorphone and
morphine treatments (Table 3). The least-squares (LS)
mean (95% CI) differences between the hydromorphone
and morphine groups were 0.2 points (0.4, 0.9) in the IR
phase and 0.8 points (1.6, 0.01) in the SR phase (ITT
population). In the IR phase, the 95% CI was within the
1.5 to 1.5 equivalency range (0.4 to 0.9), indicating
that IR hydromorphone and IR morphine were equivalent
in this primary efficacy outcome measure. In the SR phase,
the upper limit of the 95% CI was within the 1.5 boundary
(0.01), but the lower limit was less than 1.5 (1.6),
indicating that the SR formulations were not equivalent
but that the negative direction of the mean difference was
in favor of OROS® hydromorphone (Figure 3). Results of
Figure 2
Patient disposition. IR, immediate-release; SR, sustained-release.
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the analysis of the primary efficacy variable were similar
when using data from the PP population.
Secondary endpoints
At the end of the IR phase, mean scores for the secondary
efficacy variables (other assessments of pain from the
BPI [Table 3 and Figure 4], and MMSE and ECOG scores
[data not shown]) were similar for IR hydromorphone
and IR morphine, except for BPI 'pain interference with
normal work', which favored IR hydromorphone (Figure 4;
p = 0.0386).
At the end of the SR phase, scores were similar between
treatment groups for BPI items 'least pain', 'average pain',
and 'pain now AM'; however, 'pain now PM' was
significantly lower in the OROS® hydromorphone group
compared with the CR morphine group (LS mean [SE]
scores, 2.6 [0.3] versus 3.4 [0.3], respectively; p = 0.0372)
(Table 3). LS mean differences (95% CI) between
treatment groups were 0.06 (0.51, 0.64), 0.15 (0.49,
0.79), 0.38 (1.03, 0.27), and 0.77 (1.49, 0.05)
for least, average, morning, and evening pain, respectively
(Figure 3). Figures 5 and 6 show the consistency of
response to both OROS® hydromorphone and morphine
throughout the SR phase, during both the morning and
evening assessments of BPI 'pain now' scores.
LS mean BPI 'pain relief' at endpoint was 69.7% for the
OROS® hydromorphone group and 70.0% for the CR
morphine group (95% CI for treatment difference,
8.11, 7.54). BPI 'pain interference' scores were also
similar between treatment groups at endpoint, (Figure 4),
as were LS mean ECOG performance status scores (1.8
versus 1.7 in the OROS® hydromorphone and CR
morphine groups, respectively; 95% CI for treatment
difference, 0.13, 0.26), and LS mean MMSE scores
(28.9 versus 29.2; 95% CI for treatment difference,
1.19, 0.51).
The majority of both investigators and patients (> 70%)
rated the treatments as good, very good, or excellent at
the end of each study phase (Figure 7). Mean ± SD
patient global assessment scores at the end of the SR
phase were 3.2 ± 1.14 for the OROS® hydromorphone
group and 3.3 ± 0.98 for the CR morphine group
(p = 0.6696); mean ± SD investigator global assessment
scores were 3.2 ± 1.07 and 3.3 ± 0.91, respectively
(p = 0.4760).
Table 2: Demographic and baseline clinical characteristics
Characteristic Hydromorphone (N = 99) Morphine (N = 101)
Mean (SD) age, years 60.7 (12.50) 59.0 (11.36)
Gender, % male 46.5 51.5
Race, % Caucasian/Black/Asian/Other 100/0/0/0 97/0/2/1
Mean (SD) height, cm 166.7 (9.33) 167.3 (10.47)
Mean (SD) weight, kg 66.3 (15.33) 67.4 (13.33)
Mean (SD) BMI, kg/m2 23.8 (5.14) 24.2 (5.06)
Cancer type, n (%)
Breast 23 (23.2) 33 (32.7)
Lung 20 (20.2) 19 (18.8)
Genitourinary 18 (18.2) 12 (11.9)
Gastrointestinal 17 (17.2) 15 (14.9)
Oral cavity 3 (3.0) 3 (3.0)
Lymphoma 3 (3.0) 0
Leukemia 1 (1.0) 2 (2.0)
Bone 1 (1.0) 1 (1.0)
Other 13 (13.1) 16 (15.8)
Predominant pain type, n (%)
Bone or soft tissue 61 (61.6) 72 (71.3)
Mixed 19 (19.2) 15 (14.9)
Visceral 19 (19.2) 14 (13.9)
Mean (SD) MMSE score* 28.5 (2.3) 28.8 (2.0)
Mean (SD) ECOG score 1.6 (0.8) 1.6 (0.9)
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; MMSE, Mini-Mental State Examination; SD, standard deviation
*Hydromorphone, n = 75; morphine, n = 73
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Table 3: BPI scores at baseline, end of IR phase, and end of SR phase (ITT population)
Variable Baseline* Mean (SD) End of IR phase† LS mean (SE) End of SR phase‡ LS mean (SE)
Worst pain
Hydromorphone 6.3 (2.7) 5.0 (0.3) 3.5 (0.3)
Morphine 6.2 (2.5) 4.8 (0.3) 4.3 (0.3)
Least pain
Hydromorphone 2.7 (2.5) 1.8 (0.2) 1.8 (0.2)
Morphine 2.9 (2.7) 2.2 (0.2) 1.8 (0.2)
Average pain
Hydromorphone 5.0 (2.1) 3.6 (0.2) 3.4 (0.3)
Morphine 5.1 (2.1) 3.6 (0.2) 3.2 (0.3)
Pain now AM
Hydromorphone 4.0 (2.7) 3.3 (0.3) 2.4 (0.3)
Morphine 4.1 (2.4) 3.4 (0.3) 2.8 (0.3)
Pain now PM
Hydromorphone 4.8 (3.0) 3.6 (0.3) 2.6 (0.3)§
Morphine 4.2 (2.5) 3.7 (0.3) 3.4 (0.3)
Abbreviations: BPI, Brief Pain Inventory; CR, controlled-release; IR, immediate-release; LS, least-squares; SD, standard deviation; SE, standard error;
SR, sustained-release
*Hydromorphone, n = 99; morphine, n = 101
†IR hydromorphone, n = 99; IR morphine, n = 101
‡OROS® hydromorphone, n = 77; CR morphine, n = 86
§p = 0.0372 versus CR morphine
Figure 3
Least-squares mean differences and 95% confidence intervals between the OROS® hydromorphone and
controlled-release (CR) morphine groups at end of the sustained-release (SR) phase.
BMC Palliative Care 2008, 7:17 http://www.biomedcentral.com/1472-684X/7/17
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In both treatment phases, patients in the hydromor-
phone group took longer than those in the morphine
group to achieve stable doses (p < 0.001). The number of
patients requiring dose-level changes during the SR
phase was similar for both groups (19 of 77 [24.7%]
OROS® hydromorphone recipients and 23 of 86 [26.7%]
CR morphine recipients). Comparison of dosage levels at
the end of the SR phase generally showed that similar
proportions of patients received OROS® hydromorphone
or CR morphine at each of the 5 (approximate 1:5
hydromorphone to morphine) lower dosage levels,
although more patients in the OROS® hydromorphone
group (10% versus 2% in the CR morphine group)
received the highest dosage level evaluated in this study
(Table 4).
In the IR phase, 61.6% of patients taking IR hydro-
morphone and 52.5% of those receiving IR morphine
required medication for breakthrough pain on the last 2
days of the phase. In the SR phase, the corresponding
percentages in the OROS® hydromorphone and CR
morphine groups were 48.1% and 48.8%, respectively.
The mean (SD) numbers of breakthrough pain medica-
tion doses taken on the last 2 days were as follows: IR
phase, 1.8 (2.2) and 1.3 (1.8) for the IR hydromorphone
and IR morphine groups, respectively; SR phase, 1.6
(2.2) and 1.4 (1.9) for the OROS® hydromorphone and
CR morphine groups, respectively. The mean total doses
of breakthrough pain medication as a percentage of the
mean daily consumption were 39.4% and 27.1% for
hydromorphone and morphine in the IR phase, and
13.8% and 10.3% for OROS® hydromorphone and CR
morphine in the SR phase. There were no statistically
significant treatment differences in the numbers of
patients who took breakthrough pain medication or in
the amount of medication taken in either phase.
Safety
The overall safety profiles of hydromorphone and
morphine were comparable, with a similar number of
patients in each group reporting AEs. Overall, irrespective
of study phase, 81 of 99 (81.8%) hydromorphone-treated
patients and 90 of 101 (89.1%) morphine-treated
patients reported at least 1 AE.
Figure 4
Mean Brief Pain Inventory (BPI) interference scores at baseline, end of immediate-release (IR) phase, and end
of sustained-release (SR) phase. Values at baseline represent means; values at other time points represent least-squares
means. At baseline: hydromorphone, n = 99; morphine, n = 101. In IR phase: IR hydromorphone, n = 99; IR morphine, n = 101.
In SR phase: OROS® hydromorphone, n = 77; controlled-release (CR) morphine, n = 86.
BMC Palliative Care 2008, 7:17 http://www.biomedcentral.com/1472-684X/7/17
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Figure 5
Mean (standard error, SE) pain now scores in the morning during the sustained-release (SR) phase. Pain was
rated using the 11-point Brief Pain Inventory (BPI), ranging from 0 (no pain) to 10 (worst pain imaginable). CR, controlled-
release.
Figure 6
Mean (standard error, SE) pain now scores in the evening during the sustained-release (SR) phase. Pain was rated
using the 11-point Brief Pain Inventory (BPI), ranging from 0 (no pain) to 10 (worst pain imaginable). CR, controlled-release.
BMC Palliative Care 2008, 7:17 http://www.biomedcentral.com/1472-684X/7/17
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The most commonly reported AEs during the IR and SR
phases of the study are listed in Table 5. The types of AEs
were typical of those generally associated with opioid
use. The incidence of constipation was higher with
hydromorphone than morphine in both phases of the
study (23.2% versus 10.9% in the IR phase and 39.0%
versus 22.1% in the SR phase). In the SR phase, the
incidences of vomiting, nausea, and somnolence were
higher with CR morphine than with OROS® hydromor-
phone (22.1% versus 9.1%, 29.1% versus 19.5%, and
14.0% versus 10.4%, respectively). Most AEs were mild
or moderate in severity and no clear treatment difference
was seen in the relative severity of the most commonly
reported AEs. Approximately 30% of patients with AEs
reported events that were considered unlikely to be
related or not related to study therapy.
Serious AEs were reported for 24 patients during the
double-blind period (by 5 patients in each treatment
group in the IR phase, and by 7 patients in the OROS®
hydromorphone group and 9 in the CR morphine group
in the SR phase [2 patients had serious AEs in both
phases]). Many of the serious AEs were associated with
the underlying disease, although approximately one
third were considered definitely or probably related to
study therapy. Three patients in the morphine group
died during the study (2 during the IR phase, 1 during
the SR phase). None of the deaths was considered related
to the study medication.
Twenty-six patients withdrew prematurely from the
study because of AEs, 16 during the IR phase (9
hydromorphone, 7 morphine) and 10 during the SR
phase (6 OROS® hydromorphone, 4 CR morphine).
There was no statistically significant difference between
treatment groups in the time to withdrawal, irrespective
of phase (IR phase, p = 0.6537; SR phase, p = 0.2827).
The use of concomitant medications, including the use
of non-opioid analgesics, was similar for both treatment
groups in both the IR and SR phases.
Discussion
This was a short-term, randomized, double-blind com-
parative study testing the clinical equivalence of IR and
SR formulations of hydromorphone and morphine in
patients with chronic cancer pain. In each study phase
(IR and SR), mean values for BPI 'worst pain in the past
24 hours' (the primary efficacy endpoint) decreased with
Figure 7
Patient (A) and investigator (B) global evaluations of
treatment effectiveness at the end of the sustained-
release (SR) phase. CR, controlled-release.
Table 4: Dose levels at end of SR phase
OROS® hydromor-
phone (N = 77)
CR morphine (N = 86)
Dose
level
Dose (mg)
every 24
hours
Number of
subjects
(%)
Dose (mg)
every 12
hours
Number of
subjects
(%)
1 16 22 (28.6) 30 25 (29.1)
2 24 14 (18.2) 60 23 (26.7)
3 32 18 (23.4) 90 15 (17.4)
4 48 10 (13.0) 120 13 (15.1)
5 72 5 (6.5) 175 8 (9.3)
6 96 8 (10.4) 260 2 (2.3)
Abbreviations: CR, controlled-release; SR, sustained-release
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both hydromorphone andmorphine. In the IR phase, the LS
mean difference between the treatment groups was 0.2
points, and the 95% CI (0.4, 0.9) was within the pre-
specified equivalency range of 1.5 to 1.5. In the SR phase,
the LS mean difference was 0.8 points in favor of OROS®
hydromorphone. The upper limit of the 95% CI (0.01)
was within the 1.5 boundary, but the lower limit (1.6)was
less than the 1.5 limit. Therefore, according to the pre-
specified criteria, equivalence was not demonstrated; the
direction of the difference was in favor of OROS® hydro-
morphone. The BPI item 'worst pain in the past 24 hours'
was selected as the primary endpoint of the trial based on
previous studies showing it to be the most sensitive BPI
measure in the clinical trial setting [13, 20–22].
The results of the present study further suggest that
OROS® hydromorphone provides consistent pain relief
over 24 hours, and that pain levels in the evening were
significantly lower after OROS® hydromorphone compared
with CR morphine treatment. This finding reflects the 'pain
now PM' measure being scored at the end of morphine
dosing (i.e. trough levels) but at the midpoint of
hydromorphone dosing. The comparable results between
groups for the other secondary efficacy variables (including
assessments of pain interference with physical activity and
social function, performance status, and cognition) support
similarity in the treatment efficacy. Withdrawal from the
study owing to lack of efficacy was more common in
patients randomized to hydromorphone (n = 11) com-
pared with morphine (n = 4). This is a potentially negative
finding for hydromorphone; however, the numbers are too
low to draw any definite conclusions.
Results of the dose analysis were generally consistent with
those of previous reports, which indicate that most cancer
pain can be controlledwith ≤ 240mgof oralmorphine daily
[23]. In the present study, 83% of the OROS® hydromor-
phone group and 88% of the CR morphine group received
the equivalent of morphine 240 mg/day or less.
The frequency of breakthrough medication use remained
stable throughout both phases in the morphine group
Table 5: Adverse events reported by at least 5% of patients in any group during the IR or SR phase
IR phase SR phase
Adverse event Hydromorphone (N =
99)
Morphine (N = 101) OROS® hydromorphone
(N = 77)
CR morphine (N = 86)
Constipation 23 (23.2%) 11 (10.9%) 30 (39.0%) 19 (22.1%)
Nausea 18 (18.2%) 23 (22.8%) 15 (19.5%) 25 (29.1%)
Vomiting 16 (16.2%) 19 (18.8%) 7 (9.1%) 19 (22.1%)
Somnolence 11 (11.1%) 11 (10.9%) 8 (10.4%) 12 (14.0%)
Dizziness 8 (8.1%) 6 (5.9%) 4 (5.2%) 8 (9.3%)
Headache 8 (8.1%) 6 (5.9%) 3 (3.9%) 2 (2.3%)
Diarrhea 8 (8.1%) 1 (1.0%) 7 (9.1%) 2 (2.3%)
Pruritus 4 (4.0%) 5 (5.0%) 3 (3.9%) 5 (5.8%)
Asthenia 5 (5.1%) 1 (1.0%) 6 (7.8%) 4 (4.7%)
Fatigue 3 (3.0%) 3 (3.0%) 4 (5.2%) 6 (7.0%)
Confusion 2 (2.0%) 2 (2.0%) 7 (9.1%) 2 (2.3%)
Anemia 2 (2.0%) 1 (1.0%) 3 (3.9%) 6 (7.0%)
Anorexia 1 (1.0%) 4 (4.0%) 2 (2.6%) 5 (5.8%)
Insomnia 1 (1.0%) 2 (2.0%) 5 (6.5%) 4 (4.7%)
Peripheral edema 0 3 (3.0%) 1 (1.3%) 8 (9.3%)
Pyrexia 2 (2.0%) 1 (1.0%) 4 (5.2%) 2 (2.3%)
Anxiety 1 (1.0%) 1 (1.0%) 5 (6.5%) 1 (1.2%)
Abbreviations: CR, controlled-release; IR, immediate-release; SR, sustained-release
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(52.5% in the IR phase, 48.8% in the SR phase), but
decreased from the IR phase to the SR phase in the
OROS® hydromorphone group (from 61.6% to 48.1%).
At the end of the SR phase, there was no significant
difference between the groups in use of breakthrough
medication.
The occurrence of 3 deaths and 23 serious AEs during
the study was not unexpected, given the severity of the
patients' conditions and the progressive nature of the
disease. In fact, many of the serious AEs were associated
with the underlying disease.
The participants in this study are representative of the
overall population afflicted with chronic cancer pain.
The mean baseline BPI score for 'worst pain in the past
24 hours' was 6.3 on an 11-point scale, a score indicative
of moderate to severe pain [16]. This is comparable to
baseline values in other studies of cancer pain, for which
the mean score was 6.99 [24]. Baseline cognition was
similar to that of healthy controls (mean MMSE score,
28.3) [25], and the lack of change observed in both
treatment groups probably reflects the fact that the
MMSE was designed to measure cognition in Alzheimer's
disease [14] and was not intended to measure cognition
in non-demented subjects.
The major positive aspect of this study was the robust
design: it was multicenter, randomized, double-blind,
and active controlled. It also used a widely utilized and
well validated primary outcome measure, the BPI. On
the negative side, there was a relatively poor completion
rate, with only 60 out of 99 patients (60.6%) rando-
mized to hydromorphone and 73 out of 101 patients
(72.3%) randomized to morphine completing both
treatment phases. However, this completion rate was
reasonably good when taking into consideration that
this study was carried out in patients with cancer which
was advanced enough to require strong opioid analge-
sics. In addition, a dropout rate of at least 30% was
anticipated. Furthermore, the duration of the study was
relatively short (up to 24 days), so it was not possible to
make evaluations of the sustained efficacy of the
formulations.
Two previous randomized, double-blind, crossover
studies have compared CR formulations of hydromor-
phone and morphine in patients with cancer pain [26,
27]. Moriarty et al (N = 100) found no significant
differences between treatment groups for any outcome
measure, and AEs were mild and infrequent [27]. In the
other study (N = 87), patients treated with hydromor-
phone had significantly higher pain scores and required
more doses of rescue analgesia than patients receiving
morphine [26]. In addition, more patients in the
hydromorphone group withdrew owing to AEs or
inadequate analgesia (n = 16 versus n = 2 on morphine).
Although it is difficult to directly compare the results
of these studies with those of the current study, the
observed differences may reflect, at least in part,
the more consistent delivery of hydromorphone with
the OROS® formulation relative to the dosing used in
those studies. The consistent release of hydromorphone
over 24 hours has been demonstrated in previous
studies, in which steady-state plasma concentrations
were achieved by 48 hours and sustained throughout the
dosing interval [8, 28].
Practicing clinicians are acutely aware of the need for
multiple pain management alternatives, because it is
clear that the response to a particular opioid agent varies
among individuals. Although our understanding of the
causes of individual differences remains incomplete,
receptor and receptor-binding studies suggest that they
may result not only from differences in the class of
opioid receptors to which each agent binds (morphine
binds to mu [primary] and kappa [lesser extent] [29];
hydromorphone binds to mu [primary] and delta [lesser
extent] [30]), but also from inter-individual differences
in opioid receptors (several receptor subtypes have been
identified [mu 1, mu 2, mu 3, delta 1, delta 2, kappa 1,
kappa 2, kappa 3]) and the location of these variants
within the nervous system [31–33]. Therefore, clinicians
may need to utilize different opioids to achieve
maximum efficacy for each patient. In addition, some
studies have supported the use of opioid rotation,
switching from one opioid to another when treatment-
limiting toxicity results in reduced responsiveness [34–
37]. Based on numerous observations that individual
response varies greatly from opioid to opioid, changing
to a different drug may provide an improved balance
between analgesia and adverse effects; as a result, there is
a need for additional long-acting opioids on the market.
Long-acting opioid formulations such OROS® hydro-
morphone have the potential to improve the overall
management of chronic pain. Such formulations provide
more consistent opioid plasma concentrations, avoiding
the peaks and troughs associated with short-acting
agents, and result in well-tolerated, around-the-clock
pain control with fewer daily doses [38, 39].
Conclusion
This study demonstrates that while IR hydromorphone is
equivalent to IR morphine for relieving chronic cancer
pain, equivalence was not demonstrated for OROS®
hydromorphone and CR morphine in the SR phase of
the study. The direction of the mean difference between
the treatments, and the out-of-range lower limit of the
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95% CI was in favor of OROS® hydromorphone on the
primary endpoint 'worst pain'. 'Pain now PM' scores
were also significantly lower for those taking OROS®
hydromorphone at the end of the SR phase (although
the timing of this measure coincided with a trough in the
dosing levels for the twice-daily morphine compared
with the once-daily OROS® hydromorphone), and BPI
'interference with normal work' scores were significantly
lower for IR hydromorphone. None of the other
secondary efficacy analyses showed significant treatment
differences in either phase. The overall safety profiles of
the 2 treatments were generally similar and most AEs
were typical of opioid analgesic therapy.
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